# 04_QA_REPORT --- PP-0178 Histopathologic Classification

## Identity

-   **PP ID:** PP-0178
-   **Title:** Histopathologic Classification
-   **QA Report ID:** QA-PP-0178
-   **Version:** 1.0.0
-   **QA Date:** 2026-08-09
-   **Status:** PASS --- GOLD --- READY FOR INTEGRATION

## QA Executive Summary

PP-0178 has been produced after the Project Coordinator approved and
locked the complete Decision Batch according to the recommended scope.

The package was checked against:

-   the locked Gold Population Package Specification v1.0;
-   CORE_WORKING_RULES v1.6;
-   the approved Discussion depth/format reference;
-   current PP Registry architecture;
-   relevant gastric-cancer clinical source materials.

The package intentionally preserves full depth. No governed section has
been compacted merely to reduce artifact length.

------------------------------------------------------------------------

# Layer 1 --- Content QA

## 1.1 Scope respected

**PASS**

The package remains focused on:

> **histopathologic characterization of gastric cancer after tissue
> acquisition.**

It does not silently expand into:

-   detailed endoscopy;
-   biopsy technique;
-   complete staging;
-   detailed Lauren classification;
-   molecular classification;
-   biomarker-specific testing;
-   treatment algorithms.

## 1.2 Completeness

**PASS**

The CKO contains:

-   metadata;
-   educational objectives;
-   scope;
-   included topics;
-   excluded topics;
-   40 independent clinical knowledge blocks;
-   patient explanations;
-   clinical importance;
-   key concepts;
-   evidence anchors;
-   common misconceptions;
-   key messages;
-   knowledge graph;
-   revision history.

The 40-block architecture is deliberately full-depth and follows the
established project principle that knowledge should be organized into
independent blocks rather than compressed into a short narrative.

## 1.3 Internal consistency

**PASS**

The package consistently distinguishes:

-   histologic type;
-   grade/differentiation;
-   invasion;
-   stage;
-   Lauren classification;
-   molecular classification;
-   biomarker testing.

No internal section treats these as interchangeable.

## 1.4 Boundary consistency

**PASS**

The four-part Boundary is consistent across the CKO, Knowledge Passport,
Evidence Package and final production response.

------------------------------------------------------------------------

# Layer 2 --- Clinical QA

## 2.1 Clinical accuracy

**PASS**

Core clinical statements are anchored to the supplied NCCN, NCI and
ESMO--ASCO materials.

## 2.2 Guideline consistency

**PASS**

NCCN v2.2026 is used as the primary current gastric-cancer guideline
source for:

-   biopsy pathology elements;
-   EMR pathology elements;
-   gastrectomy pathology elements;
-   histologic type;
-   grade;
-   invasion;
-   vascular/lymphatic invasion;
-   margins;
-   lymph-node reporting;
-   treatment-effect assessment;
-   histologic subtype/biomarker interface.

## 2.3 Unsupported claims

**PASS**

No unsupported exhaustive WHO taxonomy, numerical diagnostic threshold,
individual prognostic prediction or individualized treatment
recommendation has been introduced.

Where the supplied sources do not support exhaustive detail, the package
explicitly preserves the evidence boundary.

## 2.4 Clinical safety

**PASS**

The package is educational.

It does not provide:

-   individualized diagnosis;
-   individualized treatment selection;
-   individualized prognosis;
-   instructions to alter treatment;
-   false reassurance from a limited biopsy.

## 2.5 Pathology/staging distinction

**PASS**

The package clearly states that pathology contributes to staging but is
not equivalent to TNM stage.

## 2.6 Specimen-specific distinction

**PASS**

Biopsy, EMR/ESD and gastrectomy pathology are treated as distinct
information contexts.

------------------------------------------------------------------------

# Layer 3 --- Educational QA

## 3.1 Patient friendliness

**PASS**

Technical terms are introduced with patient-facing explanations.

## 3.2 Terminology

**PASS**

Terms such as:

-   histopathology;
-   histologic type;
-   intestinal;
-   diffuse;
-   signet-ring;
-   poorly cohesive;
-   grade;
-   differentiation;
-   invasion;
-   margins;
-   lymphovascular invasion;

are explained before being used as higher-level concepts.

## 3.3 Logical flow

**PASS**

The CKO follows a clinical learning progression:

**tissue**

→ **microscopic examination**

→ **histologic characterization**

→ **type/pattern**

→ **grade/differentiation**

→ **invasion**

→ **specimen-specific findings**

→ **staging interface**

→ **Lauren / molecular / biomarkers**

→ **clinical integration**.

## 3.4 Misconception control

**PASS**

Fifteen clinically relevant misconceptions are explicitly addressed.

Examples include:

-   histology ≠ stage;
-   diffuse ≠ metastatic;
-   poorly differentiated ≠ stage IV;
-   signet-ring ≠ automatically hereditary;
-   biopsy ≠ complete tumor characterization;
-   histology ≠ treatment prescription.

## 3.5 Full-depth compliance

**PASS --- ABSOLUTE**

The package was not compacted.

The depth standard is treated as an absolute production constraint:

> **Never shorter or more compact than the approved Gold reference
> standard; equal depth is the minimum, and deeper is allowed where
> clinically justified.**

------------------------------------------------------------------------

# Layer 4 --- Governance QA

## 4.1 Four-artifact structure

**PASS**

The package contains exactly:

1.  01_CKO.md
2.  02_KNOWLEDGE_PASSPORT.md
3.  03_PRIMARY_EVIDENCE_PACKAGE.md
4.  04_QA_REPORT.md

## 4.2 Gold Specification compliance

**PASS**

The artifact architecture follows the locked Gold Population Package
Specification v1.0.

## 4.3 Source-first compliance

**PASS**

Clinical scope and evidence were grounded in the project Source Files.

## 4.4 User-controlled sequence

**PASS**

PP-0178 was produced because it was explicitly requested and its
Decision Batch was explicitly approved/locked.

No automatic advancement to another PP was performed.

## 4.5 Boundary compliance

**PASS**

The final production Boundary uses the required ownership structure:

-   Core
-   Supporting
-   Explicitly Excluded
-   Delegated-to PP

## 4.6 ZIP packaging

**PASS**

All four governed Markdown artifacts are packaged into one ZIP.

## 4.7 Naming compliance

**PASS**

The ZIP filename contains both:

-   PP identifier;
-   package title.

------------------------------------------------------------------------

# Traceability / QA Matrix

  -----------------------------------------------------------------------
  QA Requirement          Result                  Evidence
  ----------------------- ----------------------- -----------------------
  Correct PP identity     PASS                    PP-0178

  Approved scope used     PASS                    Locked Decision Batch

  Full-depth requirement  PASS                    40 CKBs + expanded
                                                  QA/evidence structure

  CKO structure           PASS                    Gold Specification

  Knowledge Passport      PASS                    Gold Specification

  Evidence Package        PASS                    Gold Specification

  QA Report               PASS                    Four-layer QA

  Primary clinical        PASS                    NCCN v2.2026
  guideline                                       

  Disease-specific        PASS                    NCI PDQ
  evidence                                        

  Oncology pathology      PASS                    ESMO--ASCO
  framework                                       

  Evidence traceability   PASS                    Evidence matrix +
                                                  source traceability

  Boundary                PASS                    Four-part ownership
                                                  boundary

  Adjacent PP separation  PASS                    PP-0177 / PP-0179 /
                                                  PP-0180 / PP-0181+

  Unsupported expansion   PASS                    Explicit
  avoided                                         exclusions/evidence
                                                  gaps

  Treatment advice        PASS                    Educational scope
  avoided                                         

  ZIP package             PASS                    Four artifacts

  Filename includes PP +  PASS                    Package filename
  title                                           

  Repository readiness    PASS                    Ready
  -----------------------------------------------------------------------

# Final Boundary

**Boundary: Core = gastric-cancer-specific histopathologic
characterization after biopsy or resection, including the meaning and
purpose of histopathology, microscopic recognition of gastric
adenocarcinoma, major intestinal and diffuse patterns,
tubular/papillary/mucinous forms, signet-ring-cell and poorly cohesive
morphology, mixed features, linitis plastica as a diffuse/infiltrative
pathologic concept, histologic type, tumor grade/differentiation at a
conceptual level, invasion, specimen-specific pathology differences
between biopsy/EMR/ESD/gastrectomy, relevant vascular/lymphatic invasion
and margins, pathology contribution to staging, clinical-pathologic
discordance, pathology review, and the interface with Lauren
classification, molecular classification and biomarker testing;
Supporting = dysplasia-versus-invasive-carcinoma distinction,
treatment-effect assessment in selected post-treatment specimens,
lymph-node pathology as a staging interface, pathology/IHC interface,
histologic heterogeneity, and patient-facing interpretation of technical
pathology terminology; Explicitly Excluded = detailed endoscopic
diagnosis, endoscopic biopsy strategy, pathology-report literacy,
complete TNM staging, detailed Lauren Classification methodology,
exhaustive WHO taxonomy, molecular classification methodology,
individual biomarker testing/interpretation, NGS methodology,
genomic-report interpretation, EMR/ESD or gastrectomy technique, HDGC
genetics/surveillance, precursor-lesion management, H. pylori
testing/eradication, laboratory fixation/processing methodology,
individualized prognosis, and individualized treatment recommendations;
Delegated-to PP = PP-0177 Endoscopic Biopsy Strategy, PP-0179 Lauren
Classification, PP-0180 Gastric Cancer Molecular Classification,
PP-0181--PP-0187 Biomarker/NGS Testing, PP-0189 Genomic Test Results /
How to Read a Molecular Report, PP-0190--PP-0191 Biomarker-guided
Treatment, PP-0159 HDGC Endoscopic Surveillance, PP-0165--PP-0169
precursor/risk packages, PP-0192--PP-0194 Endoscopic Resection/EMR/ESD,
and dedicated staging/surgical/pathology methodology packages.**

# Final QA Decision

## **PASS --- GOLD --- READY FOR INTEGRATION.**

This package is complete, source-grounded, structurally compliant,
full-depth, and ready for integration.
